The risk of acute rejection and the influence of induction agents in lower-risk African American kidney transplant recipients receiving modern immunosuppression

Clinical Transplantation

Volumn 28, Issue 3, 2014, Pages 292-298

  Gralla, Jane ^a,b   Le, Charles N ^a   Cooper, James E ^a   Wiseman, Alexander C ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b University of Colorado Denver and Children s Hospital Colorado   (United States)

Author keywords

African American; Disparities in outcomes; Kidney transplantation

Indexed keywords

MYCOPHENOLIC ACID; PANEL REACTIVE ANTIBODY; PREDNISONE; TACROLIMUS;

ADULT; AFRICAN AMERICAN; ANESTHESIA INDUCTION; ARTICLE; CONTROLLED STUDY; ETHNICITY; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; REGISTER; RISK FACTOR; SURVIVAL RATE;

AFRICAN AMERICAN; DISPARITIES IN OUTCOMES; KIDNEY TRANSPLANTATION;

ADULT; AFRICAN AMERICANS; ETHNIC GROUPS; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RISK FACTORS;

EID: 84895929646     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12311     Document Type: Article

References (24)

1. Kerman RH, Kimball PM, Van Buren CT et al. Influence of race on crossmatch outcome and recipient eligibility for transplantation. Transplantation 1992: 53: 64.
2. Neylan JF. Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. Transplantation 1997: 64: 1277.
3. Alkalin E, Neylan JF. The influence of Duffy blood group on renal allograft outcome in African Americans. Transplantation 2003: 75: 1496.
4. Zachary AA, Steinberg AG, Bias WB, Leffel MS. The frequencies of HLA alleles and haplotypes and their distribution among donors and renal patients in the UNOS registry. Transplantation 1996: 62: 272.
5. Butkus DE, Dottes AL, Meydrech EF, Barber WH. Effect of poverty and other socioeconomic variables on renal allograft survival. Transplantation 2001: 72: 261.
6. Young CJ, Gaston RS. Renal transplantation in black Americans. N Engl J Med 2000: 343: 1545.
7. Epstein AM, Ayanian JZ, Keogh JH et al. Racial disparities in access to renal transplantation - appropriate or due to under use or overuse? N Engl J Med 2000: 343: 1537.
8. Weng FL, Israni AK, Joffe MM et al. Race and electronically measured adherence to immunosuppressive medications after deceased donor renal transplantation. J Am Soc Nephrol 2005: 16: 1839.
9. Lamb KE, Lodhi S, Meier-Kriesche H-U. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011: 11: 450.
10. Nashan B, Light S, Hardie IR et al. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation 1999: 67: 110.
11. Vincenti F, Kirkman R, Light S et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998: 338: 161.
12. Lebranchu Y, Bridoux F, Buchler M et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patient receiving MMF containing triple therapy. Am J Transplantat 2002: 2: 48.
13. Brennan DC, Daller JA, Lake KD et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006: 355: 1967.
14. Noel C, Abramowicz D, Duran D et al. Daclizumab versus antithymocyte in high-immunological-risk renal transplant recipients. J Am Soc Nephrol 2009: 20: 1385.
15. Woodle ES, First MR, Pirsch J et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008: 248: 564.
16. Hanaway MJ, Woodle ES, Mulgaonkar S et al. Alemtuzumab induction in renal transplantation. N Engl J Med 2011: 364: 1909.
17. Gralla J, Wiseman A. The impact of IL2ra induction therapy in kidney transplantation using tacrolimus- and mycophenolate-based immunosuppression. Transplantation 2010: 90: 639.
18. Fleming JN, Taber DJ, Weimer NA et al. Comparison of efficacy of induction therapy in low immunologic risk African-American kidney transplant recipients. Transpl Int 2009: 23: 500.
19. Sanders CE, Curtis JJ, Julian BA et al. Tapering or discontinuing cyclosporine for financial reasons - a single center experience. Am J Kidney Dis 1993: 21: 9.
20. Pescovitz MD, Guasch A, Gaston R et al. Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft recipients. Am J Transplant 2003: 3: 1581. Erratum in: Am J Transplant 2004: 4: 1928.
21. Patzer RE, Perryman JP, Schrager JD et al. The role of race and poverty on steps to kidney transplantation in the southeastern United States. Am J Transplant 2012: 12: 358.
22. Srinivas TR, Schold JD, Guerra G et al. Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. Am J Transplant 2007: 7: 586.
23. Ekberg H, Tedesco-Silva H, Demirbas A et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007: 357: 2562.
24. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004: 159: 702.